213 related articles for article (PubMed ID: 34847904)
1. The effect of radioiodine treatment on the characteristics of TRAb in Graves' disease.
Fang Y; Du WH; Zhang CX; Zhao SX; Song HD; Gao GQ; Dong M
BMC Endocr Disord; 2021 Nov; 21(1):238. PubMed ID: 34847904
[TBL] [Abstract][Full Text] [Related]
2. Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites.
Morgenthaler NG; Ho SC; Minich WB
J Clin Endocrinol Metab; 2007 Mar; 92(3):1058-65. PubMed ID: 17179194
[TBL] [Abstract][Full Text] [Related]
3. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease.
Kamijo K; Murayama H; Uzu T; Togashi K; Olivo PD; Kahaly GJ
Thyroid; 2011 Dec; 21(12):1295-9. PubMed ID: 22066477
[TBL] [Abstract][Full Text] [Related]
4. Thyrotrophin receptor antibody characteristics in a woman with long-standing Hashimoto's who developed Graves' disease and pretibial myxoedema.
Kamath C; Young S; Kabelis K; Sanders J; Adlan MA; Furmaniak J; Rees Smith B; Premawardhana LD
Clin Endocrinol (Oxf); 2012 Sep; 77(3):465-70. PubMed ID: 22891608
[TBL] [Abstract][Full Text] [Related]
5. TRAb elevations occurred even in the third trimester; a case of a mother of a child with neonatal thyroid dysfunction, who received radioactive iodine therapy for Graves' disease.
Suzuki N; Yoshihara A; Yoshimura Noh J; Kinoshita K; Ohnishi J; Saito M; Sugino K; Ito K
Endocr J; 2020 Oct; 67(10):1019-1022. PubMed ID: 32522908
[TBL] [Abstract][Full Text] [Related]
6. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
7. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-21 is associated with disease activity in patients with Graves' disease.
Zhang J; Zeng H; Ren M; Yan H; Xu M; Feng Z; Liang W; Yang C; Cheng H; Ding H; Yan L
Endocrine; 2014 Aug; 46(3):539-48. PubMed ID: 24287789
[TBL] [Abstract][Full Text] [Related]
9. Low Vitamin D Status is Associated with Increased Thyrotropin-Receptor Antibody Titer in Graves Disease.
Zhang H; Liang L; Xie Z
Endocr Pract; 2015 Mar; 21(3):258-63. PubMed ID: 25370319
[TBL] [Abstract][Full Text] [Related]
10. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
[TBL] [Abstract][Full Text] [Related]
11. Correlation between thyroid volume and humoral thyroid autoimmunity after radioiodine therapy in Graves' disease.
Sawicka N; Sowiński J
Endokrynol Pol; 2012; 63(1):10-3. PubMed ID: 22378091
[TBL] [Abstract][Full Text] [Related]
12. Influence of high tissue-absorbed dose on anti-thyroid antibodies in radioiodine therapy of Graves' disease patients.
Listewnik MH; Piwowarska-Bilska H; Jasiakiewicz K; Birkenfeld B
Adv Clin Exp Med; 2021 Sep; 30(9):913-921. PubMed ID: 34418335
[TBL] [Abstract][Full Text] [Related]
13. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease.
Bossowski A; Stasiak-Barmuta A; Urban M
Horm Res; 2005; 64(4):189-97. PubMed ID: 16220002
[TBL] [Abstract][Full Text] [Related]
14. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
[TBL] [Abstract][Full Text] [Related]
15. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
Chen W; Man N; Li YS; Shan ZY; Teng WP
Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Characterization of Autoantibodies to the Thyrotropin Receptor (TRAb) During Alemtuzumab Therapy: Evidence that TRAb May Precede Thyroid Dysfunction by Many Years.
Muller I; Willis M; Healy S; Nasser T; Loveless S; Butterworth S; Zhang L; Draman MS; Taylor PN; Robertson N; Dayan CM; Ludgate ME
Thyroid; 2018 Dec; 28(12):1682-1693. PubMed ID: 30351224
[TBL] [Abstract][Full Text] [Related]
17. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
[TBL] [Abstract][Full Text] [Related]
18. Specific effects of radioiodine treatment on TSAb and TBAb levels in patients with Graves' disease.
Michelangeli VP; Poon C; Topliss DJ; Colman PG
Thyroid; 1995 Jun; 5(3):171-6. PubMed ID: 7580264
[TBL] [Abstract][Full Text] [Related]
19. Thyrotrophin receptor antibody concentration and activity, several years after treatment for Graves' disease.
Nalla P; Young S; Sanders J; Carter J; Adlan MA; Kabelis K; Chen S; Furmaniak J; Rees Smith B; Premawardhana LDKE
Clin Endocrinol (Oxf); 2019 Feb; 90(2):369-374. PubMed ID: 30485487
[TBL] [Abstract][Full Text] [Related]
20. [Predictive value of thyrotropin receptor antibodies using the second generation TRAb human assay after radioiodine treatment in Graves' disease].
Zöphel K; Wunderlich G; Kopprasch C; Koch R; Franke WG; Kotzerke J
Nuklearmedizin; 2003; 42(2):63-70. PubMed ID: 12695788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
